Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01838226 · ClinicalTrials.gov registry record · NA

Randomized Controlled Trial of Group Prevention Coaching

A NA study, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
401
Enrollment target

NCT01838226: Completed NA study, sponsored by VA Office of Research and Development.

NCT01838226 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 401 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01838226, a NA study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
401 participants
Enrollment target

Study Summary

Prevention of cardiovascular disease is a primary focus of the Secretary's New Models of Care Transformational Initiative. However, prevention has been hard to accomplish. The VA is committed to using group visits to address a wide array of primary care problems. Coaching is a method to help Veterans set and reach health goals by helping them overcome barriers to behavior change. Coaching can be performed one-on-one or in groups. This study will test the effectiveness of a group prevention coaching (GPC) intervention in improving cardiovascular risk. GPCs will focus on changing a behavior of the patient's choice that is likely to lead to improvements in heart disease risk. The coach will adopt a problem-solving approach to helping Veterans make these improvements. The primary outcome will be change in 10-year risk of major cardiac event; the investigators will also assess improvements in food choice, physical activity and weight.

Primary Outcome

The primary outcome will be 10-year risk of fatal coronary event or non-fatal MI 6 months after enrollment, as measured by Framingham Risk Score. Scores range from 0 - 100, as this is a percentage of risk. Higher scores are worse, as they represent higher risk.

Interventions

  • BEHAVIORAL Problem Solving

Trial Details

FieldValue
Enrollment Target 401 participants
Start Date 2014-08-29
Est. Completion 2019-04-30
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT01838226 record still lists

NCT01838226 is an interventional study that assigns participants to a tested intervention. The registered 401 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower).

The record links to 0 conditions, and to 1 intervention - of which Problem Solving is the first listed.

NCT01838226 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01838226 about?

NCT01838226 is a clinical study titled "Randomized Controlled Trial of Group Prevention Coaching". Prevention of cardiovascular disease is a primary focus of the Secretary's New Models of Care Transformational Initiative. However, prevention has been hard to accomplish. The VA is committed to using group visits to address a wide array of primary care problems. Coaching is a method to help Veteran...

What is the current status of trial NCT01838226?

This trial is currently completed. It is a NA study. The enrollment target is 401 participants. The study started on 2014-08-29. Estimated completion is 2019-04-30.

What interventions are being tested in trial NCT01838226?

The interventions under investigation include: Problem Solving (BEHAVIORAL).

Who is sponsoring clinical trial NCT01838226?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01838226's enrollment target sits among peer trials

401 246th of 2000 higher than 1,755 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04464226 · 402 participants · Phase 3

    Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

  • NCT05183763 · 402 participants · NA

    Medication Adherence Program

  • NCT06748222 · 402 participants · Phase 3

    E-Mindfulness Approaches for Living After Breast Cancer

  • NCT06896474 · 402 participants · NA

    SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01838226, the US trial registry maintained by the National Library of Medicine. NCT01838226 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.